• Skip to primary navigation
  • Skip to main content
  • Skip to footer
National Neutropenia Network

National Neutropenia Network

Awareness, Education, Research

  • Home
  • What is Neutropenia?
    • Overview
    • Types of Neutropenia
    • Diagnosis & Testing
    • Treatment
    • Management
  • Patient & Family Support
    • Get Support from Peers
    • Personal Stories
    • Facebook Groups
    • Additional Specialists
    • FAQ
    • Newsletter Archives
  • Events
    • Annual Conference
    • Clinical Trials
    • Webinars
  • Get Involved
    • Donate
    • Junior Ambassador
    • Senior Ambassador
    • Ways to Get Involved
  • About Us
    • Leadership
    • Contact Us

X4 Pharacutical Phase 3 WHIM Trial

X4 Pharmaceutical’s (Cambridge, MA) Phase 3 WHIM trial is open now for enrollment, entitled “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of mavorixafor (X4P-001) in Patients with WHIM Syndrome with Open-Label Extension”

WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) is a rare autosomal dominant primary immunodeficiency disease caused by gain-of-function mutations in the chemokine receptor CXCR4.  CXCR4 mutations induce increased leukocyte homing and retention in the bone marrow resulting in severe chronic neutropenia and lymphopenia.

X4 Pharmaceuticals is planning to sponsor a 52-week global Phase 3 study to evaluate the safety and efficacy of mavorixafor, a once-daily oral CXCR4 antagonist, in genetically confirmed WHIM patients who are aged 12 years or older.  Mavorixafor is a first-in-class, oral, small molecule antagonist of the CXCR4 chemokine receptor that has demonstrated a favorable safety profile and dose-dependent increases in ANC and ALC in a Phase 2 study. Trial subjects will participate in a one-year trial with an opportunity to continue in the subsequent open label extension.  Travel support to study sites will be provided.

To support confirming the diagnosis of WHIM, X4 Pharmaceuticals will offer genetic testing at no charge to patients meeting eligibility criteria suggestive for the disease.  For information and support for genetic confirmation of your patients with suspected WHIM, please contact [email protected]

Filed Under: Clinical Trials

Footer

1-866-600-0799

[email protected]

P.O. Box 632
Buffalo, MN 55313

  • Personal Stories
  • Additional Specialists
  • Clinical Trials
  • Patient Handbook
  • Emergency Cards
  • Webinars
  • Subscribe to Our Mailing List
  • Donate

Copyright © 2023 National Neutropenia Network